
News|Articles|December 1, 2006
FDA Actions in Brief (December 2006)
Imatinib (Gleevec, Novartis) was approved for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia, certain forms of myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia, and unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Neffy’s first year: $72.2m in sales, 10,000 schools and broadening payer access
2
Brukinsa/rituximab cuts progression risk 43% in mantle cell lymphoma
3
New study confirms benefits of GLP-1 drugs in patients with PAD
4
Key Takeaways, Study Limitations, and the Broader Implications of CROWN for Patients, Providers, and Payers
5
































